Lightening Cream

Natural Skin-lightening and Skin-Protecting Agents

KEY FEATURES

- Skin protection
- Skin whitening
- Organic products

INTRODUCTION

Many of us love the warmth and light of the sun; however, sun exposure causes damages to most of our skin, according to experienced dermatologists. When our skin expose to sunlight, which is the primary source of ultraviolet (UV) radiation in our daily life, our skin gets darken and damaged, or accompanied by various aesthetic problems, such as wrinkles, blemishes, scarring, freckles and chloasmata, due to the generation of oxidative stress (i.e. free radicals and reactive oxygen species) in the epidermal and dermal layers. Occasionally, the UV-induced damages may even affect certain genes that control the growth and division of our skin cells, leading to the development of melanoma.

The invention reveals that a specific class of natural compounds containing in a well-known Chinese medicine provide prominent impact on improving skin condition in the in vitro and in vivo experiments. As these natural compounds are able to reduce melanin formation, they should be decent depigmentation compounds against skin darkening in addition their antioxidant competence. Herein, these natural agents are the pertinent ingredients for the formulation of skin-lightening and skin-protecting cosmeceuticals.

APPLICATION

These agents are at appropriate proportions to the formulation of potent skin-lightening and skin-protecting cosmeceuticals.

PATENT

- "Skin-protection composition containing Dendrobium-based ingredients". US Patent Appl. No. 15/352,903, filed on 16 November 2016.

Anti-cancer and Anti-obesity Cyclic Peptides

More than 10 million people are diagnosed with cancer every year in the world. Cancer has become a leading cause of death. Although numerous cancer chemotherapeutics are available today, they often have very narrow therapeutic indices and very severe side effects. In addition, cancers often develop resistance to many drugs. On the other hand, obesity, the metabolic disease, has become increasingly concerned in modern society. It affects nearly a third population of adults in the developed countries, and more than 1.9 billion adults were overweight in 2014 according to the WHO report. Many health problems such as cardiovascular diseases, type 2 diabetes, cancer and osteoarthritis are associated with obesity. There are only a few anti-obesity drugs (orlistat) approved by the FDA for long-term use. The drugs have side effects associated with high blood pressure, rapid heart eat, palpitations, drug addiction, hallucination, constipation and insomnia. To develop new anticancer and anti-obesity drugs is thus very much needed.

A large number of cyclopeptides have been synthesized due to their variety of biological activities including anticancer activity. However, cyclopeptides containing rare amino acids are seldom reported either from synthetic study or from nature. We have discovered a series of cyclopeptides containing a rare amino acid, which have not been reported before. These cyclopeptides demonstrated potent anticancer activity against a panel of cancer cell lines with IC50 values in the range of 0.05-52 nM. One of the compound also showed to be effective on reducing body weight of mice.

The invention introduces a series of novel cyclopeptide compounds with potent anticancer activities. The peptide agents also exhibit high fat-accumulation inhibitory effects with high potential against obesity.

PATENTS

- "Anti-cancer and Anti-obesity Cyclic Peptide Agents". US Patent No. 9,499,586, filed on 14 March 2013.
- "Anti-cancer and Anti-obesity Cyclic Peptide Agents". US Patent Appl. No. 15/293,516, filed on 14 October 2014.
- "Anti-cancer and Anti-obesity Cyclic Peptide Agents". TW Patent No. 1532749, filed on 15 October 2013.
- "Anti-cancer and Anti-obesity Cyclic Peptide Agents". EP Patent Appl. No. 2909227A1, filed on 16 October 2013.
- "Anti-cancer and Anti-obesity Cyclic Peptide Agents". CN Patent Appl. No. 201380048848.5, filed on 16 October 2013.

Gihon Biotech

Enquiry

Gihon Biotech Limited

Email: panwh@gihonbiotech.com
Tel: 67301251